NAFLD Biomarker

Explore the latest advances in biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). Stay informed about these key tools for diagnosis and management.

Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice

Authors: Ilagan-Ying Y, Ilagan-Ying B et al
Published in Current Gastroenterology Reports (2023)
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease, affecting a staggering 30% of the global population.
Read MoreScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice

Managing Hepatocellular Carcinoma in NAFLD: a review

Authors: Cadar R, Lupascu Ursulescu C, Vasilescu AM, et al
Published in Life (Basel) (September 2023)
Currently, there are rising levels of non-alcoholic fatty liver disease (NAFLD). With this, comes a concurrent increase in hepatocellular carcinoma (HCC) cases.
Read MoreManaging Hepatocellular Carcinoma in NAFLD: a review

Machine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential

Authors: Lee J, Westphal M, Vali Y et al.
Published in Hepatology (July 2023)
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).
Read MoreMachine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential

Discerning sex-related differences in NAFLD patients via metabolic profiling

Authors: Fotakis C, Kalafi IP, Amanitidou AI et al.
Published in Frontiers in Endocrinology (October 2023)
Research into personalised medicine for non-alcoholic fatty liver disease (NAFLD) underscores the importance of acknowledging NAFLD patients’ unique clinical phenotypes when developing targeted pharmacotherapies.
Read MoreDiscerning sex-related differences in NAFLD patients via metabolic profiling

Liver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?

Authors: Ciardullo S, Muraca E, Zerbini F et al.
Published in Liver International (September 2023)
Liver-related events contribute to a small proportion of mortality within the collective cohort of patients with non-alcoholic fatty liver disease (NAFLD).
Read MoreLiver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?

NAFLD and Pancreatic Steatosis: A Bidirectional Relationship?

Authors: Wongtrakul W, Untaaveesup S, Pausawadi N et al.
Published in European Journal of Gastroenterology & Hepatology (October 2023)
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
Read MoreNAFLD and Pancreatic Steatosis: A Bidirectional Relationship?

PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Authors: Staels B, Butruille L, Francque S
Published in Journal of Hepatology (July 2023)
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways. Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Read MorePPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

Authors: Li YY, Zheng TL, Xiao SY et al.
Published in Liver International (June 2023)
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
Read MoreBallooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

An exploration of MAFLD’s clinical utility

Authors: Ramírez-Mejía MM, Xingshun Q, Abenavoli L et al
Published in Annals of Hepatology (July 2023)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utility

NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

Authors: Younossi ZM, Golabi P, Paik JM et al.
Published in Hepatology (April 2023)
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Read MoreNAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

NAFLD and New-Onset Heart Failure: What is the Link?

Authors: Inciardi RM, Mantovani A and Targher G
Published in Current Heart Failure Reports (July 2023)
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?

Hepatic Macrophages in NAFLD: A Novel Therapeutic Target?

Authors: Vonderlin J, Chavakis T, Sieweke M et al.
Published in Cellular and Molecular Gastroenterology and Hepatology (March 2023)
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Read MoreHepatic Macrophages in NAFLD: A Novel Therapeutic Target?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES